Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6654544 | 0.90 | POLB (0.60) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL18285205 | 0.88 | TSHR (0.56) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL6653298 | 0.87 | TSHR (0.59) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL3789796 | 0.86 | ALDH1A1 (0.64) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL6657026 | 0.86 | TSHR (0.60) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL6655348 | 0.85 | ALDH1A1 (0.61) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL17707777 | 0.85 | TSHR (0.53) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL3785486 | 0.85 | TSHR (0.53) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL17707775 | 0.85 | TSHR (0.53) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL17707781 | 0.85 | TSHR (0.53) | MEN1KMT2AMAPTMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084772-A | Nilapatinib intermediate, preparation method and method for preparing Nilapatinib by using same | 重庆博腾制药科技股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-111433577-B | Temperature detection label and article management device using same | 株式会社日立制作所 | 2021-09-21 | — | — | CN | disclosed |
| US-20040199002-A1 | Process for producing(2-nitrophenyl)acetonitrile derivative and intermediate therefor | INDUSTRY CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1431278-A1 | PROCESS FOR PRODUCING (2-NITROPHENYL)ACETONITRILE DERIVATIVE AND INTERMEDIATE THEREFOR | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| EP-1327631-A2 | Fused heterocyclic compounds, their production and use as angiotensin II antagonists | Takeda Chemical Industries, Ltd. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-0518033-B1 | Fused heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-5389641-A | Fused heterocyclic compounds, having angiotensin II antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0518033-A1 | Fused heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040199002-A1 | Process for producing(2-nitrophenyl)acetonitrile derivative and intermediate therefor | DOHH, NCEH1, NOTUM | MEN1 1136/4885KMT2A 2730/4885MAPT 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.